-
Publication Venue For
-
Extracorporeal membrane oxygenation in adults receiving haematopoietic cell transplantation: an international expert statement..
11:477-492.
2023
-
Colchicine and aspirin in community patients with COVID-19 (ACT): an open-label, factorial, randomised, controlled trial..
10:1160-1168.
2022
-
Colchicine and the combination of rivaroxaban and aspirin in patients hospitalised with COVID-19 (ACT): an open-label, factorial, randomised, controlled trial..
10:1169-1177.
2022
-
Tixagevimab-cilgavimab for treatment of patients hospitalised with COVID-19: a randomised, double-blind, phase 3 trial..
10:972-984.
2022
-
Baricitinib versus dexamethasone for adults hospitalised with COVID-19 (ACTT-4): a randomised, double-blind, double placebo-controlled trial..
10:888-899.
2022
-
The heart of the matter: modulating therapeutic effects of adrenomedullin in cardiogenic shock..
10:224-226.
2022
-
Efficacy of interferon beta-1a plus remdesivir compared with remdesivir alone in hospitalised adults with COVID-19: a double-bind, randomised, placebo-controlled, phase 3 trial..
9:1365-1376.
2021
-
The long-term sequelae of COVID-19: an international consensus on research priorities for patients with pre-existing and new-onset airways disease..
9:1467-1478.
2021
-
Inhaled treprostinil and forced vital capacity in patients with interstitial lung disease and associated pulmonary hypertension: a post-hoc analysis of the INCREASE study..
9:1266-1274.
2021
-
Use of fibrinolytics and deoxyribonuclease in adult patients with pleural empyema: a consensus statement..
9:1050-1064.
2021
-
Geography, generalisability, and susceptibility in clinical trials..
9:330-332.
2021
-
Continuation versus discontinuation of renin-angiotensin system inhibitors in patients admitted to hospital with COVID-19: a prospective, randomised, open-label trial..
9:275-284.
2021
-
Challenges in the interpretation and application of typical imaging features of COVID-19..
8:534-536.
2020
-
Antihypertensive drugs and risk of COVID-19?.
8:e30-e31.
2020
-
Anti-influenza hyperimmune intravenous immunoglobulin for adults with influenza A or B infection (FLU-IVIG): a double-blind, randomised, placebo-controlled trial..
7:951-963.
2019
-
Anti-influenza immune plasma for the treatment of patients with severe influenza A: a randomised, double-blind, phase 3 trial..
7:941-950.
2019
-
Portable normothermic ex-vivo lung perfusion, ventilation, and functional assessment with the Organ Care System on donor lung use for transplantation from extended-criteria donors (EXPAND): a single-arm, pivotal trial..
7:975-984.
2019
-
Identification of risk loci and a polygenic risk score for lung cancer: a large-scale prospective cohort study in Chinese populations..
7:881-891.
2019
-
Genetic determinants of risk in pulmonary arterial hypertension: international genome-wide association studies and meta-analysis..
7:227-238.
2019
-
Perioperative mortality and morbidity after sublobar versus lobar resection for early-stage non-small-cell lung cancer: post-hoc analysis of an international, randomised, phase 3 trial (CALGB/Alliance 140503)..
6:915-924.
2018
-
Laparoscopic anti-reflux surgery for the treatment of idiopathic pulmonary fibrosis (WRAP-IPF): a multicentre, randomised, controlled phase 2 trial..
6:707-714.
2018
-
Global, regional, and national deaths, prevalence, disability-adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015..
5:691-706.
2017
-
The MUC5B promoter polymorphism and telomere length in patients with chronic hypersensitivity pneumonitis: an observational cohort-control study..
5:639-647.
2017
-
Less is more: a shift in the surgical approach to non-small-cell lung cancer..
4:e11-e12.
2016
-
Association of hospital admission and forced vital capacity endpoints with survival in patients with idiopathic pulmonary fibrosis: analysis of a pooled cohort from three clinical trials..
3:388-396.
2015
-
Anti-acid treatment and disease progression in idiopathic pulmonary fibrosis: an analysis of data from three randomised controlled trials..
1:369-376.
2013